Nocturia
Conditions
Brief summary
The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult men during 12 weeks treatment
Interventions
DRUGA: Desmopressin 25 µg
DRUGB. Desmopressin 50 µg
DRUGPlacebo
Sponsors
Ferring Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Has given written consent prior to any trial-related activity is performed * Male sex, aged 20 years or older * At least 2 nocturnal voids every night in a consecutive 3-day period as documented in the diary during the screening period * Has given agreement about contraception during the trial
Exclusion criteria
* Suspicion of bladder outlet obstruction or a urine flow of less than 5 mL/s as confirmed by uroflowmetry after suspicion of bladder outlet obstruction * A surgical treatment for bladder outlet obstruction or prostatic hyperplasia within the past 6 months * Showing symptoms of any of the following diseases: Benign prostatic obstruction; Interstitial cystitis; Overactive bladder, defined as \>6 daytime voids, ≥1 urgency episode, and ≥1 urge urinary incontinence episode per 24 hours as documented in the 3-day diary period; Severe stress urinary incontinence * Chronic prostatitis/chronic pelvic pain syndrome * Psychogenic or habitual polydipsia * Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention * Cancer * A history of urologic malignancies or a history of cancer which has not been in remission for the last 5 years * Genito-urinary tract pathology * Neurogenic detrusor activity * Suspicion or evidence of heart failure * Uncontrolled hypertension * Uncontrolled diabetes mellitus * Hepatobiliary diseases: Aspartate aminotransferase \>80 U/L or alanine aminotransferase \>90 U/L; Total bilirubin \>1.5 mg/dL * Renal insufficiency: Serum creatinine level \>1.09 mg/dL; Estimated glomerular filtration rate \<50 mL/min * Hyponatraemia: Serum sodium level \<135 mEq/L * Central or nephrogenic diabetes insipidus * Syndrome of inappropriate antidiuretic hormone * Obstructive sleep apnea * Previous desmopressin treatment * Treatment with another investigational product within the past 3 months * Concomitant treatment with any prohibited medication * Alcohol or substance abuse * A job or lifestyle that may interfere with regular night-time sleep * A mental condition, lack of decision-making ability, dementia, a speech handicap, or any other reason which, in the judgement of the investigator (sub-investigator), would impair the participation in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in mean number of nocturnal voids | During 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Responder status (33% reduction in nocturnal voids) | During 12 weeks |
| Change from baseline in mean number of nocturnal voids | 1, 4, 8 and 12 weeks |
| Change from baseline in mean nocturnal urine volume | 1, 4, 8 and 12 weeks |
| Change from baseline in mean time to first void | During 12 weeks |
| Change from baseline in the effect on sleep disturbance | 1, 4, 8 and 12 weeks |
| Change from baseline in the impact on quality of life | 12 weeks |
| Adverse events, changes from baseline in serum sodium level, laboratory values | During 12 weeks |
| Change from baseline in nocturnal polyuria index | 1, 4, 8 and 12 weeks |
Countries
Japan
Outcome results
None listed